Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, United Kingdom (B.M., E.G., C.P.P.); National Institute for Biological Standards and Control, South Mimms, Hertfordshire, United Kingdom (J.H., E.G.) and School of Pharmacy, University College London, London, United Kingdom (R.L.)
Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King's College London, London, United Kingdom (B.M., E.G., C.P.P.); National Institute for Biological Standards and Control, South Mimms, Hertfordshire, United Kingdom (J.H., E.G.) and School of Pharmacy, University College London, London, United Kingdom (R.L.).
Pharmacol Rev. 2023 Mar;75(2):328-379. doi: 10.1124/pharmrev.122.000684. Epub 2023 Feb 15.
Heparin has been used extensively as an antithrombotic and anticoagulant for close to 100 years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence, which potentiates the inhibitory action of antithrombin, a major inhibitor of the coagulation cascade. More recently it has been elucidated that heparin exhibits anti-inflammatory effect via interference of the formation of neutrophil extracellular traps and this may also contribute to heparin's antithrombotic activity. This illustrates that heparin interacts with a broad range of biomolecules, exerting both anticoagulant and nonanticoagulant actions. Since our previous review, there has been an increased interest in these nonanticoagulant effects of heparin, with the beneficial role in patients infected with SARS2-coronavirus a highly topical example. This article provides an update on our previous review with more recent developments and observations made for these novel uses of heparin and an overview of the development status of heparin-based drugs. SIGNIFICANCE STATEMENT: This state-of-the-art review covers recent developments in the use of heparin and heparin-like materials as anticoagulant, now including immunothrombosis observations, and as nonanticoagulant including a role in the treatment of SARS-coronavirus and inflammatory conditions.
肝素作为一种抗血栓和抗凝药物已经广泛应用近 100 年。这种抗凝活性主要归因于五糖序列,它增强了抗凝血酶的抑制作用,抗凝血酶是凝血级联的主要抑制剂。最近已经阐明,肝素通过干扰中性粒细胞胞外陷阱的形成表现出抗炎作用,这也可能有助于肝素的抗血栓活性。这表明肝素与广泛的生物分子相互作用,发挥抗凝和非抗凝作用。自我们之前的综述以来,人们对肝素的这些非抗凝作用越来越感兴趣,其中 SARS2-冠状病毒感染患者的有益作用就是一个非常热门的例子。本文在我们之前的综述基础上进行了更新,介绍了肝素的这些新用途的最新进展和观察结果,并概述了基于肝素的药物的开发状况。
本综述涵盖了肝素和肝素样物质作为抗凝剂的最新应用进展,包括免疫血栓形成观察结果,以及作为非抗凝剂的应用,包括在 SARS-冠状病毒和炎症性疾病治疗中的作用。